

Express Mail No.: **EV 475 141 820 US** 

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Srivastava Confirmation No.: 1802

Application No.: 09/873,403 Group Art Unit: 1642

Filed: June 4, 2001 Examiner: Christopher H. Yaen

For: COMPLEXES OF ALPHA(2)- Attorney Docket No.: 8449-178-999

MACROGLOBULIN AND ANTIGENIC (CAM #708584-999177)
MOLECULES FOR IMMUNOTHERAPY

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.56 AND §1.97

## MAIL STOP RCE

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the continuing duty of disclosure imposed by 37 C.F.R. §1.56 and §1.97 to inform the United States Patent and Trademark Office ("USPTO") of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Attorneys for Applicant hereby invite the Examiner's attention to references EN to EQ listed on the attached form entitled "List of References Cited by Applicant." Copies of references EN to EQ are enclosed herewith.

Identification of the listed references is not meant to be construed as an admission of Applicant or Attorneys for Applicant that such references are available as "prior art" against the subject application.

Applicant respectfully requests that the Examiner review the foregoing references and that the references be made of record in the file history of the application.

sheet 2 of 2 Attorney Docket No.: 8449-178-999 Application No.: 09/873,403 Applicant: Srivastava

This supplemental information disclosure statement is being filed along with a Request for Continued Examination under 37 C.F.R. §1.114 in connection with the subject application. Pursuant to 37 C.F.R. §1.97(b), Applicant believes that no fee is due in connection with the filing of this Supplemental Information Disclosure Statement. However, if a fee is required, please charge the amount of any such fee to Jones Day deposit account no. 50-3013.

Respectfully submitted,

Date: December 12, 2005

32,605

Adriane M. Antler

JONES DAY 222 East 41<sup>st</sup> Street

New York, New York 10017

Phone: (212) 901-9028

Express Mail No.: EV 475 141 820 US Sheet I of I APPLICATION NO. ATTY. DOCKET NO. 8449-178-999 09/873,403 RENCES CITED BY APPLICANT APPLICANT (Use several sheets if necessary) Srivastava GROUP FILING DATE 1642 June 4, 2001 U.S. PATENT DOCUMENTS \*EXAMINER FILING DATE **SUBCLASS** DOCUMENT NUMBER CLASS IF APPROPRIATE INITIAL DATE NAME

	FOREIGN PAT	ENT DOCUMENTS				
DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSL	ATIO
					YES	N
						1
		· · · · · · · · · · · · · · · · · · ·	-			$t^{-}$
 						┼

/C.Y./	EN	Rammensee et al. 1995 "MHC ligands and peptide motifs: first listing" Immunogenetics 41:178-228
/G.Y./	ЕО	Rammensee et al. 1999 "SYFPEITHI: the database for MHC ligands and peptide motifs Immunogenetics 50:213-219
/C.Y./	EP	Lovett et al. 1993 "Rubella virus specific cytotoxic T-lymphocyte responses: identification of the capsid as a target of MHC class I-restricted lysis and definition of two epitopes" J. Virology 76:5849-5858
/C.Y./	EQ	Thomson et al. 1996 "Recombinant polytopic vaccines for the delivery of multiple CD8 cytotoxic T cell epitopes" J. Immunol. 157:822-826

	EXAMINER /Christoph	ner Yaen/ (05/12/2008)	DATE CONSIDERED	05/12/2008
--	---------------------	------------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.